Navigation Links
Hemostemix Hosts Cell Therapy Industry Seminar

Toronto, Canada & Kyriat Weizmann, Israel (PRWEB) October 31, 2013

Hemostemix Ltd. and BioForum have announced a jointly-sponsored symposium entitled “Cell Therapy – an evolving industry” to be held November 4 at the Dan Hotel in Tel Aviv, Israel.

The event will feature invited speakers including Dr. Elmar Burchardt, Pfizer’s Vice President of Regenerative Medicine and cell therapy executives from Canada, United States, India, and Israel. The seminar will brief attendees on global industry trends, discuss optimal cell therapy product development, review the impact of CROs on clinical trial outcomes, present key elements of cellular product analytics, outline cell therapy business models, and engage in an open dialogue about the potential keys to cell therapy being a pillar of future healthcare.

“We are pleased to play a role in hosting an event which highlights the global cell therapy industry,” stated Hemostemix President and founder, Dr. Valentin Fulga. “With this seminar, and others planned, we want to facilitate an information-exchange and dialogue between investors, clinicians, and scientists that will promote a greater understanding of how cell therapies will shape the future of medicine.”

“Bioforum is excited to provide what it believes will be an important and useful seminar in this exciting new field of science and medicine,” stated Yehudith Wexler, Chairperson of Bioforum.
For more information about the seminar, click here.

This seminar is part of a series of presentations intended to introduce the company and its platform technology to a wide audience in the context of the cell therapy industry’s progress and maturation. This includes a recent keynote presentation (“Synergetic Cell Population – a powerful tool for autologous therapies”) delivered October 23rd in Orlando, FL and an upcoming presentation (“A peripheral blood-derived cellular population can be differentiated into neural like progenitor cells”) at the TERMIS-AM 2013 Conference to be held November 10-13in Atlanta, Georgia.

About Hemostemix Ltd

Hemostemix Ltd is a Canadian-Israeli company developing and commercializing innovative blood-derived cell therapies for medical conditions not adequately addressed by current treatments with an operating research, development and manufacturing facility in Kiryat Weizmann Science Park, Ness Ziona. For more information see

About Bioforum

Established in 1998, Bioforum provides a wide range of services in the areas of Education and Training, Clinical Data, Regulatory Submissions and Clinical Supply (inPACK). Bioforum's strategic lines of business combine professional services, process optimization, technology and education. Bioforum maximizes their costumers’ benefits by providing cost effective outsourcing and consultation services for the pharmaceutical, medical and medical device industries. For more information about Bioforum, see

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Hemostemix Announces Formation of Scientific Advisory Board
2. Hemostemix Announces US Patent Allowance
3. The Hemostemix Group of Companies Provides Corporate Strategy Update
4. Funding Tomorrow's Biomedical Research: California Healthcare Institute Hosts Pipeline for Life, July 15
5. DTx Hosts Webinar on New Intel® Haswell Platform
6. Black Data Processing Associates (BDPA) New Jersey Hosts 10th Annual Families in Technology Day June 8, 2013
7. Industry Leader Linguamatics Hosts Record-breaking Spring Users Conference in Cambridge, UK
8. Cambridge College School of Management Program Hosts a Panel Discussion On Trends and Opportunities In Health Information Technology
9. San Diego State University Hosts Open House for Life Science Immersion Biotechnology Program
10. Ultra Light Startups Hosts Future Energy Investor Feedback Forum at MIT
11. Bayer CropScience Hosts Third Sustainability in Agriculture: A Bayer Executive Course
Post Your Comments:
(Date:11/25/2015)... Oregon , November 25, 2015 ... Market Research Report is a professional and in-depth ... industry.      (Logo: ) ... overview of the industry including definitions, classifications, applications ... is provided for the international markets including development ...
(Date:11/24/2015)... , Nov. 24, 2015  Asia-Pacific (APAC) ... research organisation (CRO) market. The trend of outsourcing ... lower margins but higher volume share for the ... and scale, however, margins in the CRO industry ... (CRO) Market ( ), finds that ...
(Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... speaking at the following conference, and invited investors to ... NY      Tuesday, December 1, 2015 at 11.00 ... NY      Tuesday, December 1, 2015 at 11.00 ... Conference, New York, NY      Tuesday, ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" ... reported financial results for the quarter ended September ... in Canadian dollars and presented under International Financial ... States ," said Andrew Rae , ... regarding iCo-008 are not only value enriching for ...
Breaking Biology Technology:
(Date:11/17/2015)... -- Vigilant Solutions announces today that Mr. Dick W. ... --> --> Mr. Boyce ... at TPG Capital, one of the largest global investment ... revenue.  He founded and led TPG,s Operating Group, which ... 1997 to 2013.  In his first role, he served ...
(Date:11/12/2015)... golden retriever that stayed healthy despite having the gene ... new lead for treating this muscle-wasting disorder, report scientists ... and Harvard and the University of São Paolo in ... pinpoints a protective gene that boosts muscle regeneration, ... Children,s lab of Lou Kunkel , PhD, is ...
(Date:11/11/2015)... MedNet Solutions , an innovative SaaS-based eClinical technology company that ... announce that it will be a Sponsor of the ... held November 17-19 in Hamburg , Germany.  ... iMedNet , MedNet,s easy-to-use, proven and affordable eClinical ... able to deliver time and cost savings of up to ...
Breaking Biology News(10 mins):